[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2024007541A - Compounds. - Google Patents

Compounds.

Info

Publication number
MX2024007541A
MX2024007541A MX2024007541A MX2024007541A MX2024007541A MX 2024007541 A MX2024007541 A MX 2024007541A MX 2024007541 A MX2024007541 A MX 2024007541A MX 2024007541 A MX2024007541 A MX 2024007541A MX 2024007541 A MX2024007541 A MX 2024007541A
Authority
MX
Mexico
Prior art keywords
compounds
solvates
antagonists
prevention
useful
Prior art date
Application number
MX2024007541A
Other languages
Spanish (es)
Inventor
Stefan Schunk
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW111148705A external-priority patent/TW202325719A/en
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2024007541A publication Critical patent/MX2024007541A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
MX2024007541A 2021-12-20 2022-12-20 Compounds. MX2024007541A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21216012 2021-12-20
EP22201323 2022-10-13
TW111148705A TW202325719A (en) 2021-12-20 2022-12-19 Compounds
PCT/EP2022/086854 WO2023118049A1 (en) 2021-12-20 2022-12-20 Compounds

Publications (1)

Publication Number Publication Date
MX2024007541A true MX2024007541A (en) 2024-07-04

Family

ID=84923122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007541A MX2024007541A (en) 2021-12-20 2022-12-20 Compounds.

Country Status (8)

Country Link
US (1) US11957761B2 (en)
EP (1) EP4453004A1 (en)
KR (1) KR20240116921A (en)
AU (1) AU2022420665A1 (en)
CA (1) CA3241530A1 (en)
IL (1) IL313590A (en)
MX (1) MX2024007541A (en)
WO (1) WO2023118049A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62142147A (en) 1985-12-17 1987-06-25 Kurita Water Ind Ltd Diphenic acid bis dicyclohexylamide and sustained release antimicrobial agent containing said compound
KR20180095809A (en) 2015-11-11 2018-08-28 인사이클 세라퓨틱스, 인코포레이티드 a cyclic peptide targeting the alpha 4 beta 7 integrin
CA3042576A1 (en) 2016-11-11 2018-05-17 Encycle Therapeutics, Inc. Cyclic peptides multimers targeting .alpha.4.beta.7 integrin
KR20200015540A (en) 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 Homocyclic Cyclic Peptides Targeting α4β7 Integrin
CN110862380A (en) 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 Small molecule compound
TW202214669A (en) 2020-06-29 2022-04-16 丹麥商西蘭製藥公司 Compounds

Also Published As

Publication number Publication date
WO2023118049A1 (en) 2023-06-29
AU2022420665A1 (en) 2024-06-06
US11957761B2 (en) 2024-04-16
KR20240116921A (en) 2024-07-30
IL313590A (en) 2024-08-01
US20230190946A1 (en) 2023-06-22
CA3241530A1 (en) 2023-06-29
EP4453004A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
MXPA05009595A (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses.
ATE449081T1 (en) FLUORALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
TW200505449A (en) Pharmaceutical compositions and dosage forms of thalidomide
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
UA85597C2 (en) Quaternary salt ccr2 antagonists
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
SA521421973B1 (en) CRF1 Receptor Antagonist, Pharmaceutical Formulations and Solid Forms Thereof for The Treatment of Congenital Adrenal Hyperplasia
DE602005002562D1 (en) PYRROLYL SUBSTITUTED PYRIDOE2,3-DIPYRIMIDIN-7-ONE AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS
ATE384724T1 (en) CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS
ATE402176T1 (en) PYRROLIDINE AND AZETIDINE COMPOUNDS ALSCCR5 ANTAGONISTS
CY1106763T1 (en) PREVENTIVE OR THERAPEUTIC MEANS FOR INFLAMMATORY BOWEL DISEASES
MX2022006736A (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases.
GEP20237476B (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
PH12020551772A1 (en) Oxo-substituted compound
NZ785829A (en) Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease
MY148125A (en) Compounds
MXPA05012953A (en) 3-arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents.
HK1090543A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
NO20071399L (en) VLA-4 antagonists
MX2022011697A (en) Cyclophilin inhibitors and uses thereof.
DE60006542D1 (en) CONNECTIONS THAT INHIBIT TRYPTASE ACTIVITY
TW200724143A (en) Novel compounds for the treatment of inflammatory diseases
MX2024000043A (en) Caspase-2 inhibitor compounds.
MX2024007541A (en) Compounds.